Electronic Supplementary Material (ESI) for Toxicology Research.

SUPPLEMENTARY DATA

Table 1S. Hematological and clinical chemistry parameters in B6C3F1 mice dermally administered triclosan for 13 weeks[a]

		Dose (mg triclosan/kg bw/day)																
		0[c]			*5.8*			*12.5*			*27*			*58*			*125*	
Parameters	***Unit***	***N***[b]	***Mean***	***SE***	***N***	***Mean***	***SE***	***N***	***Mean***	***SE***	***N***	***Mean***	***SE***	***N***	***Mean***	***SE***	***N***	***Mean***	***SE***
									Female mice									
WBC	$10^3/mm^3$	10	3.47*	0.26	10	4.86	0.70	10	4.12	0.72	10	4.86	0.49	10	6.20**	0.87	8	5.38*	0.74
NEU	%	10	4.05	0.42	10	2.83	0.38	10	3.30	0.41	10	4.01	0.47	10	2.91	0.25	8	3.14	0.13
	$10^3/mm^3$	10	0.14	0.02	10	0.14	0.03	10	0.13	0.03	10	0.20	0.04	10	0.18	0.03	8	0.17	0.03
LYM	%	10	85.89*	0.84	10	88.84	1.11	10	88.26	1.17	10	87.33	1.03	10	89.18*	0.87	8	85.61	0.56
	$10^3/mm^3$	10	2.99	0.23	10	4.36	0.65	10	3.62	0.61	10	4.24	0.44	10	5.57**	0.82	8	4.62	0.67
MON	%	10	8.42***	0.64	10	6.31	0.69	10	6.85	0.76	10	7.08	0.70	10	6.87	0.73	8	10.46	0.52
	$10^3/mm^3$	10	0.29***	0.03	10	0.29	0.05	10	0.31	0.08	10	0.34	0.04	10	0.40	0.04	8	0.54***	0.06
EOS	%	10	0.56**	0.10	10	0.46	0.17	10	0.45	0.17	10	0.48	0.11	10	0.23	0.08	8	0.18**	0.04
	$10^3/mm^3$	10	0.02**	0.00	10	0.02	0.01	10	0.01	0.00	10	0.02	0.01	10	0.01	0.00	8	0.01*	0.00
BAS	%	10	1.08*	0.19	10	1.56	0.49	10	1.14	0.29	10	1.10	0.22	10	0.81	0.14	8	0.61	0.10
	$10^3/mm^3$	10	0.04	0.01	10	0.07	0.02	10	0.04	0.01	10	0.05	0.01	10	0.04	0.01	8	0.03	0.01
RBC	$10^6/mm^3$	10	9.84***	0.12	10	9.72	0.14	10	9.70	0.13	10	9.60	0.14	9	9.53	0.09	7	8.71***	0.14
HGB	g/dL	10	15.25***	0.21	10	15.11	0.27	10	15.04	0.19	10	14.70	0.22	9	14.44**	0.14	7	13.00***	0.15
HCT	%	10	46.68***	0.67	10	47.06	0.74	10	47.39	0.57	10	46.87	0.71	9	46.42	0.50	7	42.63***	0.57
MCV	μm^3	10	47.50	0.27	10	48.50*	0.17	10	49.00***	0.21	10	48.80**	0.20	9	48.89***	0.20	7	48.86*	0.34
MCH	pg	10	15.51***	0.08	10	15.54	0.06	10	15.51	0.06	10	15.31	0.10	9	15.18**	0.05	7	14.91***	0.10
MCHC	g/dL	10	32.69***	0.15	10	32.07*	0.09	10	31.71***	0.08	10	31.36***	0.15	9	31.16***	0.07	7	30.49***	0.15
PLT	$10^3/mm^3$	10	678.6***	11.98	10	672.9	30.07	9	655.1	45.01	10	730.9	18.92	9	841.7***	25.39	8	1049.0***	37.93
PCV	%	10	46.65**	0.75	10	46.80	0.72	10	47.25	0.61	10	46.35	0.60	9	46.22	0.60	8	44.31	1.39
Retic	%	10	2.68	0.09	10	2.79	0.08	10	2.85	0.13	10	2.69	0.15	9	2.61	0.10	8	2.69	0.14

		Dose (mg triclosan/kg bw/day)																
		0[c]			*5.8*			*12.5*			*27*			*58*			*125*	
Parameters	***Unit***	***N[b]***	***Mean***	***SE***	***N***	***Mean***	***SE***	***N***	***Mean***	***SE***	***N***	***Mean***	***SE***	***N***	***Mean***	***SE***	***N***	***Mean***	***SE***
TP	g/dL	10	5.90	0.04	10	5.94	0.09	10	6.24**	0.10	10	5.94	0.06	10	5.89	0.12	10	5.91	0.08
ALT	U/L	10	30.30	1.80	10	29.90	2.12	10	56.60*	17.67	10	35.40	4.74	10	29.10	1.08	10	38.30	2.72
ALP	U/L	10	95.70**	3.19	10	106.2	5.80	10	124.3***	4.67	10	150.4***	6.05	10	158.6***	13.51	10	130.7**	8.98
ALB	g/dL	10	3.68***	0.04	10	3.64	0.06	10	3.74	0.05	10	3.66	0.04	10	3.54	0.06	10	3.30***	0.03
SDH	U/L	10	8.16	2.44	10	9.36	2.64	8	18.53	5.68	10	13.77	3.79	10	10.10	3.71	10	13.28	3.74
CK	U/L	10	203.3	49.97	10	263.2	53.37	9	449.2	233.7	10	265.2	42.73	10	205.8	44.28	10	155.4	50.78
BUN	mg/dL	10	23.50*	1.28	10	21.90	1.75	10	23.80	1.49	10	21.20	1.01	10	20.00	1.21	10	28.20	1.98
TRIG	mg/dL	10	122.9***	8.80	10	166.7	14.75	10	237.2***	28.03	10	249.0***	26.71	10	239.7***	9.64	10	235.2***	17.88
CREAT	mg/dL	10	0.29	0.03	10	0.27	0.02	10	0.32	0.02	10	0.29	0.02	10	0.32	0.02	10	0.28	0.02
CHOL	mg/dL	10	132.9***	4.20	10	89.50***	5.69	10	63.70***	2.23	10	43.70***	3.90	10	40.00***	3.11	10	32.20***	1.47
TBA	µmol/L	10	48.25	13.13	10	41.63	5.92	10	82.25	17.33	10	43.85	6.57	10	58.02	14.49	10	36.83	5.74
GLU	mg/dL	10	215.8	11.38	10	246.3	17.16	10	220.2	12.99	10	230.8	6.64	10	231.2	5.87	10	208.8	14.23
T4	µg/dL	8	5.60***	0.34	8	4.90	0.54	6	4.77	0.53	10	4.43*	0.27	9	3.93**	0.30	9	2.36***	0.22
T3	ng/dL	2	96.15	2.55	4	107.6	18.42	3	108.9	6.74	4	98.70	7.76	4	85.90*	2.95	6	91.10	4.35
Testosterone	ng/dL	7	3.11	0.74	9	3.76	0.91	6	4.07	1.31	10	4.18	1.03	10	3.97	0.76	9	3.76	1.16
Male mice																			
WBC	$10^3/mm^3$	9	3.59	0.44	10	4.78	0.98	10	4.29	0.68	10	3.71	0.59	10	5.65	0.77	8	5.39	0.85
NEU	%	9	5.28	0.73	10	3.44	0.55	10	3.43*	0.24	10	4.52	0.73	10	2.85**	0.26	8	4.49	0.37
	$10^3/mm^3$	9	0.19	0.02	10	0.17	0.04	10	0.15	0.03	10	0.17	0.04	10	0.17	0.03	8	0.25	0.05
LYM	%	9	84.27*	1.40	10	88.86*	1.27	10	89.08*	0.69	10	87.83	1.14	10	91.28***	0.43	8	83.64	1.35
	$10^3/mm^3$	9	3.03	0.38	10	4.30	0.91	10	3.87	0.62	10	3.23	0.51	10	5.16	0.70	8	4.47	0.68
MON	%	9	7.80***	1.21	10	5.37	0.57	10	6.36	0.47	10	4.88	0.47	10	5.28	0.35	8	10.83	1.35
	$10^3/mm^3$	9	0.28**	0.05	10	0.23	0.04	10	0.25	0.03	10	0.19	0.04	10	0.29	0.03	8	0.61	0.16
EOS	%	9	1.24*	0.75	10	0.76	0.26	10	0.34	0.10	10	0.82	0.22	10	0.11**	0.02	8	0.21	0.06

		Dose (mg triclosan/kg bw/day)																
		0[c]			5.8			12.5			27			58			125	
Parameters	**Unit**	**N[b]**	**Mean**	**SE**	**N**	**Mean**	**SE**	**N**	**Mean**	**SE**	**N**	**Mean**	**SE**	**N**	**Mean**	**SE**	**N**	**Mean**	**SE**
	$10^3/mm^3$	9	0.04	0.02	10	0.03	0.01	10	0.01	0.00	10	0.03	0.01	10	0.01	0.00	8	0.01	0.00
BAS	%	9	1.41	0.30	10	1.57	0.54	10	0.79	0.17	10	1.95	0.45	10	0.48**	0.07	8	0.84	0.16
	$10^3/mm^3$	9	0.06	0.02	10	0.05	0.01	10	0.03	0.01	10	0.07	0.02	10	0.03	0.00	8	0.04	0.01
RBC	$10^6/mm^3$	9	9.69***	0.19	10	9.73	0.14	10	9.80	0.10	9	9.74	0.09	10	9.62	0.08	8	9.12*	0.12
HGB	g/dL	9	14.71***	0.33	10	14.99	0.18	10	14.95	0.15	9	14.76	0.09	10	14.59	0.10	8	13.65*	0.20
HCT	%	9	45.71***	0.93	10	46.25	0.63	10	46.68	0.45	9	46.56	0.44	10	46.37	0.35	8	43.61*	0.63
MCV	μm^3	9	47.22*	0.22	10	47.60	0.16	10	47.50	0.22	9	47.67	0.24	10	48.10*	0.18	8	47.88	0.23
MCH	pg	9	15.17**	0.08	10	15.38	0.07	10	15.26	0.09	9	15.13	0.09	10	15.19	0.07	8	14.96	0.09
MCHC	g/dL	9	32.18***	0.20	10	32.39	0.10	10	32.05	0.09	9	31.68*	0.12	10	31.49**	0.09	8	31.26***	0.14
PLT	$10^3/mm^3$	9	637.9***	66.54	10	871.4	105.8	10	778.2	16.70	9	807.2**	11.71	10	820.6**	40.19	8	1009.4***	28.31
PCV	%	9	45.83***	0.92	10	46.40	0.58	10	46.55	0.50	9	46.44	0.46	10	46.30	0.33	8	43.31*	0.58
Retic	%	9	2.59	0.11	10	2.53	0.11	10	2.71	0.12	9	2.67	0.15	10	2.57	0.11	8	2.61	0.11
TP	g/dL	10	5.87*	0.10	10	5.82	0.12	10	5.87	0.08	10	5.82	0.07	10	5.58*	0.06	10	5.73	0.05
ALT	U/L	10	34.90***	1.92	10	32.50	1.38	10	33.00	1.51	10	35.00	1.15	10	32.80	1.36	10	41.90*	1.57
ALP	U/L	10	60.00	2.04	10	60.30	3.13	10	65.50	1.77	10	70.70**	2.83	10	67.60	2.62	10	71.00	6.03
ALB	g/dL	10	3.45***	0.05	10	3.39	0.07	10	3.46	0.04	10	3.46	0.04	10	3.27*	0.04	10	3.07***	0.05
SDH	U/L	10	12.28	3.45	10	9.99	3.02	10	13.79	4.77	10	13.84	3.12	10	13.66	3.79	10	8.75	1.97
CK	U/L	10	227.2	47.3	10	234.8	58.9	10	207.2	43.23	10	178.8	30.10	10	212.4	43.83	10	145.7	16.94
BUN	mg/dL	10	27.20*	1.13	10	24.90	1.59	10	24.40	1.17	10	23.20	1.21	10	21.20**	1.34	10	23.50	0.98
TRIG	mg/dL	10	188.6	12.41	10	181.9	16.90	10	228.0	24.70	10	196.6	25.13	10	204.3	37.74	10	226.9	23.56
CREAT	mg/dL	10	0.28	0.02	10	0.26	0.02	10	0.27	0.02	10	0.28	0.02	10	0.28	0.02	10	0.24	0.03
CHOL	mg/dL	10	144.5***	8.54	10	134.5	3.08	10	108.2***	3.80	10	88.9***	7.75	10	71.2***	6.53	10	42.5***	3.31
TBA	µmol/L	10	57.19	18.75	10	37.00	3.56	10	39.89	4.55	10	38.17	7.31	10	33.15	3.67	10	42.28	3.65
GLU	mg/dL	10	235.6	11.97	10	232.0	9.10	10	244.3	10.11	10	247.5	9.40	10	252.0	10.95	10	234.7	11.98

		Dose (mg triclosan/kg bw/day)																
		0[c]			*5.8*			*12.5*			*27*			*58*			*125*	
Parameters	***Unit***	***N[b]***	***Mean***	***SE***	***N***	***Mean***	***SE***	***N***	***Mean***	***SE***	***N***	***Mean***	***SE***	***N***	***Mean***	***SE***	***N***	***Mean***	***SE***
T4	µg/dL	10	4.25***	0.26	10	4.65	0.26	10	4.62	0.28	9	4.54	0.33	10	3.94	0.25	10	2.55***	0.17
T3	ng/dL	9	116.8***	5.48	7	126.2	6.72	7	110.4	4.64	8	109.9	4.97	5	98.74	8.09	8	87.76***	4.75
Testosterone	ng/dL	10	607.2	182.3	10	1079.8	335.1	10	733.8	144.4	9	760.8	218.2	10	558.6	151.9	9	675.8	226.7

[a]Hematological analysis: white blood cell (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), red blood cells (RBC), hemoglobin concentration (HGB), hematocrit (HCT), mean cell volume (MCV), mean cell hemoglobin (MCH), and mean cell hemoglobin concentration (MCHC), platelets (PLT), packed cell volume (PCV), and reticulocyte count (Retic); clinical chemistry analysis: total protein (TP), alanine aminotransferase (ALT), alkaline phosphatase (ALP), albumin (ALB), sorbitol dehydrogenase (SDH), creatine kinase (CK), blood urea nitrogen (BUN), triglycerides (TRIG), creatinine (CREAT), cholesterol (CHOL), total bile acids (TBA), glucose (GLU), thyroxine (T4), triiododthyronine (T3), and testosterone.

[b]Each group consisted of 10 mice/sex. The sample numbers for some of the parameters analyzed were smaller than 10 because the amount of blood collected from the animal was not sufficient to conduct all the analyses.

[c]An * in the control (0 mg triclosan/kg bw/day) column indicates a significant dose-response trend; an * in the dose column indicates a significant pairwise comparison of the dose group to the control group using Dunnett's method of adjusted contrasts (*: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$).

Table S2. Estrous cycle phases in female B6C3F1 mice dermally administered triclosan for 13 weeks[a]

Dose (mg triclosan/kg bw/day)	*Estrous stage[b]*	*Counts*	*Percent*
0	Diestrus	87	56.9
	Proestrus	31	20.3
	Estrus	35	22.9
27	Diestrus	84	52.8
	Proestrus	35	22.0
	Estrus	40	25.2
58	Diestrus	86	53.8
	Proestrus	34	21.3
	Estrus	40	25.0
125	Diestrus	74	51.7
	Proestrus	26	18.2
	Estrus	43	30.1

[a]Estrous status data were obtained from vaginal lavage performed for 16 consecutive days at the end of the study. Each group consisted of 10 animals. Data were collected for only seven and nine days for two animals in the 125 mg triclosan/kg bw/day group because they were mistakenly removed and transferred to pathology approximately one week earlier than their scheduled termination date.

[b]Sixteen samples with a transitional status were designated as follows: estrus/diestrus as estrus, diestrus/proestrus as diestrus, and proestrus/estrus as estrus. There were no significant differences in the percentages of mice in each phase of the estrous cycle as determined by Holm's method of adjustment for multiple comparisons.

Table 3S. Sperm morphology abnormality in male B6C3F1 mice dermally administered triclosan for 13 weeks[a]

Dose (mg triclosan/kg bw/day)	*Type*	*Number of abnormalities*	*Number of animals*	*Percent*
0	Head	0	10	100.0
	Tail	0	6	60.0
		1	3	30.0
		2	1	10.0
	Total	0	6	60.0
		1	3	30.0
		2	1	10.0
27	Head	0	9	90.0
		1	1	10.0
	Tail	0	8	80.0
		1	2	20.0
	Total	0	7	70.0
		1	3	30.0
58	Head	0	10	100.0
	Tail	0	6	60.0
		1	4	40.0
	Total	0	6	60.0
		1	4	40.0
125	Head	0	10	100.0
	Tail	0	6	60.0
		1	3	30.0
		2	1	10.0
	Total	0	6	60.0
		1	3	30.0
		2	1	10.0

[a]Each group consisted of 10 mice. Sperm abnormalities were analyzed using a generalized linear model with a Poisson distribution and a log link function. None of the triclosan dose groups differed from the control (0 mg triclosan/kg bw/day) group as determined by Hochberg's method of adjustment for multiple comparisons.

Table 4S. Sperm motility and sperm counts of cauda and testes in male B6C3F1 mice dermally administered triclosan for 13 weeks[a]

	Dose (mg triclosan/kg bw/day)											
	0			***27***			***58***			***125***		
	Mean	***SE***	***P value***	***Mean***	***SE***	***P value***	***Mean***	***SE***	***P value***	***Mean***	***SE***	***P value***
Sperm motility (%)	88.0	1.8	0.595	87.1	2.3	0.981	88.5	1.7	0.997	86.2	2.4	0.876
Cauda sperm counts ($\times 10^6$/g tissue)	895.3	80.9	0.752	839.2	57.4	0.910	875.1	90.9	0.995	907.4	62.0	0.999
Testes sperm counts ($\times 10^6$/g tissue)	274.5	14.5	0.925	273.4	14.7	1.000	257.9	22.1	0.912	278.1	32.2	0.999

[a]Each group consisted of 10 mice. P-values in the control (0 mg triclosan/kg bw/day) column represent the analysis of a linear dose-related trend; p-values in the dose column represent a pairwise comparison of the dose group to the control group using Dunnett's method of adjusted contrasts (*: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$).

Table 5S - Benchmark dose modeling results (mg triclosan/kg bw/day) of non-neoplastic skin lesions in female and male B6C3F1 mice dermally administered triclosan for 13 weeks[a]

Endpoint	Sex	Model	AIC[b]	Fitted model[c]	GOF[d]	BMD[e]	BMDL[f]
Fibrosis, dermis	Female	Gamma	29.0	0.826	0.888	17.4	9.9
		Logistic	31.7	0.373	0.490	19.4	12.8
		Log-Logistic	29.0	0.819	0.891	17.8	10.9
		Log-Probit	28.5	0.901	0.940	17.9	11.2
		Multistage	27.8	0.803	0.921	14.6	8.2
		Probit	31.0	0.473	0.566	19.0	12.4
		Weibull	29.6	0.709	0.817	16.4	8.7
	Male	Gamma	22.8	0.999	1.000	27.7	17.3
		Logistic	23.3	0.960	0.980	31.3	20.8
		Log-Logistic	23.1	0.984	0.994	28.4	18.4
		Log-Probit	22.9	0.997	0.999	27.7	18.3
		Multistage	22.9	0.822	0.919	18.9	12.7
		Probit	23.0	0.988	0.994	22.6	19.5
		Weibull	22.9	0.997	0.999	28.3	16.5
Inflammation, dermis	Female	Gamma	47.7	0.357	0.510	8.4	3.3
		Logistic	46.3	0.306	0.450	8.5	5.7
		Log-Logistic	46.1	0.444	0.606	9.1	4.8
		Log-Probit	45.9	0.490	0.637	9.1	4.9
		Multistage	47.8	0.227	0.373	7.1	2.6
		Probit[g]	46.6	0.272	0.430	8.2	5.7
		Weibull	47.2	0.286	0.455	7.7	2.8
	Male	Gamma	28.3	0.932	0.959	23.6	13.9

		Logistic	29.6	0.716	0.790	27.8	18.6
		Log-Logistic	29.0	0.824	0.896	24.1	14.7
		Log-Probit	28.5	0.901	0.940	23.8	15.0
		Multistage	26.8	0.931	0.984	19.4	11.7
		Probit	29.0	0.817	0.868	26.2	17.4
		Weibull	28.3	0.931	0.962	23.3	13.1
Hyperplasia, epidermis	Female	Gamma	14.4	1.000	1.000	8.1	5.4
		Logistic	16.2	1.000	1.000	11.5	5.6
		Log-Logistic	14.2	1.000	1.000	10.6	5.7
		Log-Probit	16.2	1.000	1.000	10.0	5.6
		Multistage	18.9	0.459	0.743	4.2	2.3
		Probit	16.2	1.000	1.000	10.6	5.4
		Weibull	16.3	1.000	1.000	9.1	5.3
	Male	Gamma	31.8	0.711	0.797	7.8	3.6
		Logistic	34.0	0.367	0.487	8.8	5.6
		Log-Logistic	32.2	0.644	0.751	8.1	4.6
		Log-Probit	31.6	0.757	0.827	8.2	4.8
		Multistage	30.1	0.790	0.868	7.4	2.8
		Probit	33.4	0.442	0.544	8.5	5.4
		Weibull	32.1	0.663	0.777	7.1	3.2
Inflammation, epidermis	Female	Gamma	49.2	0.970	0.971	10.2	3.4
		Logistic	47.7	0.943	0.942	9.3	6.3
		Log-Logistic	49.2	0.966	0.981	11.8	5.2
		Log-Probit	49.1	0.985	0.991	11.6	5.3
		Multistage	49.6	0.898	0.898	9.0	3.0
		Probit	47.8	0.928	0.929	8.8	6.2

		Weibull	49.4	0.934	0.935	9.0	3.2
	Male	Gamma	24.2	0.994	0.997	28.5	17.7
		Logistic	24.7	0.944	0.968	32.7	21.9
		Log-Logistic	24.7	0.949	0.975	29.5	18.7
		Log-Probit	24.4	0.977	0.989	28.5	18.7
		Multistage	23.7	0.881	0.959	20.5	13.6
		Probit	24.4	0.979	0.989	30.7	20.4
		Weibull	24.2	0.995	0.998	28.8	16.8
Necrosis, epidermis	Female	Gamma	49.0	0.378	0.498	16.3	7.3
		Logistic	47.5	0.465	0.604	17.0	11.6
		Log-Logistic	49.8	0.280	0.417	16.7	8.2
		Log-Probit	49.3	0.336	0.469	16.6	8.6
		Multistage	49.0	0.379	0.487	17.1	6.4
		Probit	47.2	0.512	0.642	15.8	11.0
		Weibull	48.9	0.390	0.506	16.0	7.1
	Male	Gamma	37.5	0.853	0.913	15.2	7.4
		Logistic	39.0	0.591	0.723	21.1	14.2
		Log-Logistic	38.5	0.684	0.805	15.7	8.4
		Log-Probit	38.2	0.737	0.831	15.3	8.7
		Multistage	37.3	0.889	0.937	15.1	6.6
		Probit	38.4	0.690	0.794	19.7	13.4
		Weibull	37.3	0.893	0.936	15.2	7.5
Ulcer, epidermis	Male	Gamma	25.6	0.576	0.541	48.3	33.2
		Log-Logistic	25.6	0.583	0.545	54.1	36.1
		Log-Probit	27.6	0.415	0.380	53.1	35.1
		Multistage	30.8	0.088	0.188	27.0	19.4

		Weibull	27.6	0.415	0.380	53.6	31.2
	Male	Gamma	14.3	1.000	1.000	47.7	32.8
		Logistic	16.2	1.000	1.000	55.7	35.3
		Log-Logistic	14.2	1.000	1.000	53.8	35.6
		Log-Probit	16.2	1.000	1.000	52.8	34.6
		Multistage	19.4	0.395	0.719	26.7	19.3
		Probit	16.2	1.000	1.000	53.5	32.7
		Weibull	16.2	1.000	1.000	53.2	30.8
Parakeratosis	Female	Gamma	50.0	0.169	0.274	4.1	2.5
		Log-Logistic	49.9	0.176	0.284	5.3	1.8
		Log-Probit	49.4	0.209	0.306	5.8	2.2
		Multistage	50.0	0.169	0.285	3.7	2.5
		Weibull	50.0	0.168	0.281	3.9	2.5
	Male	Gamma	35.1	0.250	0.324	13.7	6.8
		Log-Logistic	34.8	0.275	0.361	14.0	8.0
		Log-Probit	34.2	0.345	0.422	14.4	8.5
		Multistage	34.0	0.274	0.316	14.4	5.2
		Weibull	35.8	0.193	0.287	12.3	5.8

[a]Benchmark doses (BMD) and the lower 95% confidence limits (BMDL) were calculated using Environmental Protection Agency Benchmark Dose Software (version 2.4.0.70; http://www.epa.gov/ncea/bmds). The calculations were conducted using gamma, logistic, log-logistic, log-probit, multistage, probit, and Weibull models to fit the non-neoplastic skin lesion incidences and the doses of triclosan administered dermally. The BMD was defined as the dose that caused a 10% excess risk of the specified adverse effect over that observed in the appropriate control group.

[b]AIC, Akaike information criterion.

[c]p-value of fitted model compared to the full model.

[d]GOF, Goodness of fit p-value.

[e]BMD, benchmark dose (mg triclosan/kg bw/day)

[f]BMDL, lower 95% confidence limit of benchmark dose (mg triclosan/kg bw/day).

Figure 1S: Body weights of female and male B6C3F1 mice dermally administered 0, 5.8, 12.5, 27, 58, or 125 mg triclosan/kg bw/day for 13 weeks.